Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Pharmaxis secures $4.4 million in placement to support ongoing myelofibrosis and skin scarring clinical studies

% of readers think this story is Fact. Add your two cents.


Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has received commitments from sophisticated and institutional investors to subscribe for 54.6 million fully paid ordinary shares at A$0.08 per share to raise around A$4.4 million.

New shareholder Karst Peak Capital Limited has invested A$3.2 million for an 8.9% holding in the company and existing shareholder BVF Partners LP invested A$800,000 to maintain its holding at 19.5%.

Funds raised will be used to strengthen the balance sheet as the company conducts a phase 1/2 study in myelofibrosis with its lead drug PXS-5505 (which is already recruiting) and a phase 1c study in patients with problematic skin scarring with its topical drug PXS-6302.

The company will have a A$20 million pro-forma cash balance (as of March 31, 2021) post raising.

“Major shareholder recognises pipeline potential”

New major shareholder Karst Peak is based in Hong Kong and Sydney focusing on equity investments in listed companies in the consumer, healthcare, and technology sectors in Asia and Australasia.

Pharmaxis chief executive officer Gary Phillips said: “We are delighted to welcome Karst Peak as a major shareholder as we commence clinical studies that will deliver results that will have significant value to both patients and shareholders.

“This recognition of the potential in our pipeline from an institutional fund that is renowned for its extensive due diligence prior to investing is very encouraging at a time when we are focusing our resources on clinical trials and looking to deliver non-dilutive cash and cost savings from other parts of our business.”

In addition, existing shareholder BVF Partners LP has committed to invest a further A$800,000 to maintain its shareholding in the company to 19.5%.  

Russian deal boosts financial footing

Further strengthening the balance sheet, Pharmaxis also announced today the sale of the distribution rights in Russia for its cystic fibrosis product Bronchitol.

Regional pharma specialty company GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) has purchased the rights for A$2 million – effective May 1, 2021.

Phillips said the company was delighted that key functions would now be handled by GEN, a trusted business partner in other territories for more than seven years.  

“Pharmaxis steered Bronchitol to approval as the first orphan drug approved in Russia following a change in legislation, listing on the Essential Drugs List and subsequently established a fast-growing business that brought a new drug to cystic fibrosis patients in Russia.  

“We have had a long and productive collaboration with GEN who have been our distributors in the Turkish market for many years.  

“Extending this relationship to encompass Russia and other related territories at this time will ensure that Bronchitol will be well supported by an experienced partner with a leading position in cystic fibrosis care.”

“Cost savings strengthen balance sheet”

Seventy per cent of the distributor appointment fee is now payable to Pharmaxis with the remaining 30 per cent due in 12 months.

In addition to the sale price, the company has secured ongoing annual savings of A$1 million in marketing and regulatory expenses. 

Phillips said: “The upfront payments and the annual cost savings realised by the company along with today’s placement strengthen our balance sheet as we commence clinical proof of concept studies in myelofibrosis and skin scarring.  

“Further initiatives currently underway to generate non-dilutive cash and reduce operating expenses will be announced as they are completed.” 

Pharmaxis will continue to manufacture and export Bronchitol to Russia from its factory in Sydney that also supplies the US, European and Australian markets.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/946496/pharmaxis-secures-44-million-in-placement-to-support-ongoing-myelofibrosis-and-skin-scarring-clinical-studies-946496.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.